Your account is not claimed yet. You can sign up with ORCID to claim your account.

Janet K Coller

ORCID

Publication Activity (10 Years)

Years Active: 2019-2023
Publications (10 Years): 9

Top Venues

Cancer chemotherapy and pharmacology

British journal of clinical pharmacology

Brain sciences

Cancers

University of Adelaide

University of Adelaide (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

University of Adelaide

Australia

Senior Lecturer :: Pharmacology

Education History

University of Adelaide

Australia

PHD

Publications

Samantha K Korver, Joanne M Bowen, Rachel J Gibson, Imogen A Ball, Kate R Secombe, Taylor J Wain, Richard M Logan, Jonathan Tuke, Kelly R Mead, Alison M Richards, Christos S Karapetis, Dorothy M Keefe, Janet K Coller
Advanced statistics identification of participant and treatment predictors associated with severe adverse effects induced by fluoropyrimidine-based chemotherapy. Cancer chemotherapy and pharmacology 91 (6) (2023)
Amanda S Maddern, Janet K Coller, Joanne M Bowen, Rachel J Gibson
The Association between the Gut Microbiome and Development and Progression of Cancer Treatment Adverse Effects. Cancers 15 (17) (2023)
Samantha K Korver, Joanne M Bowen, Rachel J Gibson, Imogen A Ball, Kate R Secombe, Taylor J Wain, Richard M Logan, Jonathan Tuke, Kelly R Mead, Alison M Richards, Christos S Karapetis, Dorothy M Keefe, Janet K Coller
Advanced statistics identification of participant and treatment predictors associated with severe adverse effects induced by fluoropyrimidine-based chemotherapy. Cancer chemotherapy and pharmacology 91 (6) (2023)
Samantha K Korver, Joanne M Bowen, Rachel J Gibson, Imogen A Ball, Kate R Secombe, Taylor J Wain, Richard M Logan, Jonathan Tuke, Kelly R Mead, Alison M Richards, Christos S Karapetis, Dorothy M Keefe, Janet K Coller
Advanced statistics identification of participant and treatment predictors associated with severe adverse effects induced by fluoropyrimidine-based chemotherapy. Cancer chemotherapy and pharmacology (2023)
Samantha K Korver, Joanne M Bowen, Rachel J Gibson, Imogen A Ball, Kate R Secombe, Taylor J Wain, Richard M Logan, Jonathan Tuke, Kelly R Mead, Alison M Richards, Christos S Karapetis, Dorothy M Keefe, Janet K Coller
Advanced statistics identification of participant and treatment predictors associated with severe adverse effects induced by fluoropyrimidine-based chemotherapy. Cancer chemotherapy and pharmacology 91 (6) (2023)
Benedetta C Sallustio, Benjamin D Noll, Rong Hu, Daniel T Barratt, Jonathan Tuke, Janet K Coller, Graeme R Russ, Andrew Alexander Somogyi
Tacrolimus dose, blood concentrations and acute nephrotoxicity, but not CYP3A5/ABCB1 genetics, are associated with allograft tacrolimus concentrations in renal transplant recipients. British journal of clinical pharmacology 87 (10) (2021)
Janet K Coller, Jonathan Tuke, Taylor J Wain, Emily Quinn, Lea Steele, Maria Abreu, Kristina Aenlle, Nancy Klimas, Kimberly Sullivan
Associations of Immune Genetic Variability with Gulf War Illness in 1990-1991 Gulf War Veterans from the Gulf War Illness Consortium (GWIC) Multisite Case-Control Study. Brain sciences 11 (11) (2021)
Elise E Bruning, Janet K Coller, Hannah R Wardill, Joanne M Bowen
Site-specific contribution of Toll-like receptor 4 to intestinal homeostasis and inflammatory disease. Journal of cellular physiology 236 (2) (2020)
Janet K Coller, Jeyamani Ramachandran, Libby John, Jonathan Tuke, Alan Wigg, Matthew Doogue
The impact of liver transplant recipient and donor genetic variability on tacrolimus exposure and transplant outcome. British journal of clinical pharmacology 85 (9) (2019)

Janet K Coller.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Janet K Coller